AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by AYTU BIOPHARMA, INC. on November 16, 2022. The report discloses a significant corporate event regarding the passing of Michael Macaluso, the Company's Co-Founder and founding board member.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statement data.
Material Changes
The primary material change reported is the death of Michael Macaluso, a key executive and board member. No financial or operational changes were detailed in this specific filing.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or management commentary on future operations. The primary risk disclosed is the loss of a founding leader, which may impact strategic direction or governance, though specific contingencies are not detailed in the text.
Key Facts for Investor Verification
- Michael Macaluso, Co-Founder and founding board member, passed away on November 16, 2022.
- The Company's press release regarding this event is attached as Exhibit 99.1.
- The report was signed by Mark Oki, Chief Financial Officer.
- No financial performance data is included in this specific filing.